The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine plus oxaliplatin changes serious adverse events compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether gemcitabine changes serious adverse events compared with vandetanib (very low certainty).
The review found no eligible studies for this question.
The intervention may leads to higher serious adverse events2,4 (low certainty).
Hysterectomy (simple or radical) with radiotherapy may leads to higher severe/serious adverse events compared with radiotherapy alone (low certainty).
The review found no eligible studies for this question.